Human Organoids Market Report 2026

Human Organoids Market Overview

• Human Organoids market size has reached to $1.71 billion in 2025 • Expected to grow to $3.61 billion in 2030 at a compound annual growth rate (CAGR) of 16.1% • Growth Driver: Rising Genetic Research Experiments Fueling The Growth Of The Market Due To Advancements In Stem Cell And Gene Editing Technologies • Market Trend: Innovative Oxygen-Permeable Culture Technology Enhances 3D Cell Growth And In Vitro Modeling Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Organoids Market?

Human organoids are three-dimensional, miniature, lab-grown versions of human organs created from stem cells. They mimic the structure and function of real organs on a small scale and are used in research to study human development, disease, and drug testing in a controlled environment. The main types of human organoids are brain organoids, heart organoids, intestinal organoids, kidney organoids, liver organoids, lung organoids, and pancreatic organoids. Brain organoids are miniature, lab-grown models of the human brain developed from stem cells. These organoids are developed using advanced technologies such as 3D bioprinting, cell culture technology, hydrogels and scaffold-based technology, and magnetic levitation for various applications, such as drug discovery, infectious disease research, neurology studies, oncology research, personalized medicine, and regenerative medicine. The primary end users of these organoids include pharma and biotech companies, contract research organizations, and academic and research institutes.

What Is The Human Organoids Market Growth Forecast?

The human organoids market size is expected to see rapid growth in the next few years. It will grow to $3.61 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising pharmaceutical r&d spending, expansion of organoid applications in regenerative medicine, technological advances in 3d cell culture systems, growing demand for human-relevant disease models. Major trends in the forecast period include growing adoption of organoids in drug discovery and toxicity testing, increasing use of organoids for disease modeling and pathophysiology studies, rising demand for personalized medicine using patient-derived organoids, expansion of organoid applications in oncology and neurology research, increasing collaboration between academia and pharma for organoid-based research.

Global Human Organoids Market Segmentation

1) By Type: Brain Organoids, Heart Organoids, Intestinal Organoids, Kidney Organoids, Liver Organoids, Lung Organoids, Pancreatic Organoids 2) By Technology: 3D Bioprinting, Cell Culture Technology, Hydrogels And Scaffold-Based Technology 3) By Application: Drug Discovery, Infectious Disease Research, Neurology Studies, Oncology Research, Personalized Medicine 4) By End User: Pharma And Biotech Companies, Contract Research Organizations, Academic And Research Institutes Subsegments: 1) By Brain Organoids: Cerebral Organoids, Midbrain Organoids, Hypothalamic Organoids, Spinal Cord Organoids 2) By Heart Organoids: Cardiac Muscle Organoids, Vascularized Heart Organoids, Chamber-Specific Heart Organoids 3) By Intestinal Organoids: Small Intestine Organoids, Colon Organoids, Duodenal Organoids 4) By Kidney Organoids: Nephron Organoids, Glomerular Organoids, Proximal Tubule Organoids 5) By Liver Organoids: Hepatic Organoids, Bile Duct Organoids, Cholangiocyte Organoids 6) By Lung Organoids: Airway Organoids, Alveolar Organoids, Bronchial Organoids 7) By Pancreatic Organoids: Islet Organoids, Ductal Pancreatic Organoids, Acinar Pancreatic Organoids

What Is The Driver Of The Human Organoids Market?

The rising number of experiments in genetic science is expected to drive the growth of the human organoids market going forward. Genetic science is the branch of biology that studies how traits are inherited through genes and how genetic information influences the development and function of living organisms. The number of experiments in genetic science is rising due to technological breakthroughs that make gene editing faster and more precise. It enables deeper research into diseases and the development of targeted treatments. Genetic science benefits human organoids by allowing accurate manipulation of genes to model specific diseases and study their development. It helps researchers understand genetic disorders, test new drugs, and explore personalized treatment strategies more effectively. For instance, in April 2024, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, reported that in Q4 2023, the number of phase III gene therapy clinical trials rose by 10%, marking the first quarterly increase since Q3 2022. Therefore, the rising number of experiments in genetic science will drive the human organoids industry.

Key Players In The Global Human Organoids Market

Major companies operating in the human organoids market are Organovo Holdings Inc., Emulate Inc., MIMETAS B.V., InSphero AG, DefiniGEN Limited, CN Bio Innovations Limited, CELLINK AB, Hubrecht Organoid Technology, Stemcell Technologies Inc., Crown Bioscience Inc., Synthego Corporation, Altis Biosystems Inc., Molecular Devices LLC, TissUse GmbH, Nortis Inc., Hesperos Inc., Vivodyne Inc., Curi Bio Inc., Axol Bioscience Ltd.

Global Human Organoids Market Trends and Insights

Major companies operating in the human organoids market are focusing on developing advanced culture platforms and materials that enhance cell viability and oxygen delivery to improve the accuracy and scalability of in vitro models for drug discovery, regenerative medicine, and personalized therapy applications. For instance, in June 2025, Mitsui Chemicals Group, a Japan-based chemical manufacturing company, has introduced its InnoCell oxygen-permeable cell culture microplates. These novel microplates combine the company’s specialized materials and precision cutting techniques to enhance oxygen delivery to cells, especially useful in 3D spheroid and organoid cultures, reducing cell death and improving long-term viability. They come in both non-treated (N-type) and collagen-coated (C-type) versions for diverse cell types. The plates also feature low drug adsorption and excellent fluorescence imaging properties. With these advancements, the product is positioned to support drug discovery, personalized medicine, regenerative therapies, and advanced in vitro modeling in pharmaceutical research.

What Are Latest Mergers And Acquisitions In The Human Organoids Market?

In January 2025, Merck Group, a Germany-based pharmaceutical company, acquired HUB Organoids Holding B.V. for an undisclosed amount. With this acquisition, Merck aims to strengthen its next-generation biology portfolio by integrating cutting-edge organoid technology to accelerate drug development, improve treatment insights across populations, and reduce animal testing, reinforcing its commitment to innovative and ethical life sciences solutions. HUB Organoids Holding B.V. is a Netherlands-based biotechnology company specializing in human organoid research and applications.

Regional Outlook

North America was the largest region in the human organoids market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Organoids Market?

The human organoids market include revenues earned by entities by providing services such as drug discovery and development, disease modeling, toxicology testing, regenerative medicine research, and biomarker discovery. The market value includes the value of related goods sold by the service provider or included within the service offering. The human organoids market also consists of sales of products including organoid-based therapeutics, disease modeling solutions, drug testing platforms, and research applications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Organoids Market Report 2026?

The human organoids market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human organoids industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.